The role of CD95/CD95 Ligand Signaling in Apoptosis and Cancer

Apoptosis and Cancer Therapy: From Cutting-edge Science to Novel Therapeutic Concepts

Volumn 1, Issue , 2008, Pages 3-30

  Gülow, Karsten ^a   Kamiński, Marcin ^a   Krammer, Peter H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antiapoptotic proteins; Apoptosis; Biology; Cancer; Mitochondrial stress

Indexed keywords

EID: 84891289607     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619665.ch1     Document Type: Chapter

References (168)

1. Kerr, J. F., A. H. Wyllie and A. R. Currie. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239.
2. Ellis, H. M. and H. R. Horvitz. 1986. Genetic control of programmed cell death in the nematode C. elegans. Cell 44:817.
3. Kroemer, G., B. Dallaporta and M. Resche-Rigon. 1998. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60:619.
4. Hengartner, M. O. 2000. The biochemistry of apoptosis. Nature 407:770.
5. Thornberry, N. A. and Y Lazebnik. 1998. Caspases: enemies within. Science 281:1312.
6. Petit, P. X., S. A. Susin, N. Zamzami, B. Mignotte and G. Kroemer. 1996. Mitochondria and programmed cell death: back to the future. FEBS Lett 396:7.
7. Skulachev, V. P. 1996. Why are mitochondria involved in apoptosis? Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-producing mitochondria and cell. FEBS Lett 397:7.
8. Cory, S. and J. M. Adams. 2002. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647.
9. Liu, X., C. N. Kim, J. Yang, R. Jemmerson and X. Wang. 1996. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86:147.
10. Du, C., M. Fang, Y. Li, L. Li and X. Wang. 2000. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33.
11. Joza, N., S. A. Susin, E. Daugas, W. L. Stanford, S. K. Cho, C. Y. Li, T. Sasaki, A. J. Elia, H. Y. Cheng, L. Ravagnan, K. F. Ferri, N. Zamzami, A. Wakeham, R. Hakem, H. Yoshida, Y. Y. Kong, T. W. Mak, J. C. Zuniga-Pflucker, G. Kroemer and J. M. Penninger. 2001. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 410:549.
12. Li, L. Y., X. Luo and X. Wang. 2001. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412:95.
13. Parrish, J., L. Li, K. Klotz, D. Ledwich, X. Wang and D. Xue. 2001. Mitochondrial endonuclease G is important for apoptosis in C. elegans. Nature 412:90.
14. Suzuki, Y., Y. Imai, H. Nakayama, K. Takahashi, K. Takio and R. Takahashi. 2001. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 8:613.
15. Lorenzo, H. K. and S. A. Susin. 2004. Mitochondrial effectors in caspase-independent cell death. FEBS Lett 557:14.
16. Faccio, L., C. Fusco, A. Chen, S. Martinotti, J. V. Bonventre and A. S. Zervos. 2000. Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J Biol Chem 275:2581.
17. Krueger, A., S. C. Fas, S. Baumann and P. H. Krammer. 2003. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev 193:58.
18. Dempsey, P. W, S. E. Doyle, J. Q. He and G. Cheng. 2003. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 14:193.
19. Walczak, H. and M. R. Sprick. 2001. Biochemistry and function of the DISC. Trends Biochem Sci 26:452.
20. Cascino, I., G. Fiucci, G. Papoff and G. Ruberti. 1995. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154:2706.
21. Krammer, P. H. 2000. CD95's deadly mission in the immune system. Nature 407:789.
22. Watanabe, D., T. Suda and S. Nagata. 1995. Expression of Fas in B cells of the mouse germinal center and Fas-dependent killing of activated B cells. Int Immunol 7:1949.
23. Suda, T., T. Takahashi, P. Golstein and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169.
24. Oshimi, Y., S. Oda, Y. Honda, S. Nagata and S. Miyazaki. 1996. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 157:2909.
25. French, L. E., M. Hahne, I. Viard, G. Radlgruber, R. Zanone, K. Becker, C. Muller and J. Tschopp. 1996. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 133:335.
26. Lee, J., J. H. Richburg, S. C. Younkin and K. Boekelheide. 1997. The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology 138:2081.
27. Mitsiades, C. S., V. Poulaki and N. Mitsiades. 2003. The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer. J Endocrinol 178:205.
28. Siegel, R. M., J. K. Frederiksen, D. A. Zacharias, F. K. Chan, M. Johnson, D. Lynch, R. Y. Tsien and M. J. Lenardo. 2000. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288:2354.
29. Krueger, A., S. C. Fas, S. Baumann and P. H. Krammer. 2003. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev 193:58.
30. Algeciras-Schimnich, A., L. Shen, B. C. Barnhart, A. E. Murmann, J. K. Burkhardt and M. E. Peter. 2002. Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 22:207.
31. Muzio, M., A. M. Chinnaiyan, F. C. Kischkel, K. O'Rourke, A. Shevchenko, J. Ni, C. Scaffidi, J. D. Bretz, M. Zhang, R. Gentz, M. Mann, P. H. Krammer, M. E. Peter and V M. Dixit. 1996. FLICE, a novel FADD-homologous ICE/CED-3 -like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817.
32. Medema, J. P., C. Scaffidi, F. C. Kischkel, A. Shevchenko, M. Mann, P. H. Krammer and M. E. Peter. 1997. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBOJ 16:2794.
33. Muzio, M., B. R. Stockwell, H. R. Stennicke, G. S. Salvesen and V M. Dixit. 1998. An induced proximity model for caspase-8 activation. J Biol Chem 273:2926.
34. Krueger, A., S. Baumann, P. H. Krammer and S. Kirchhoff. 2001. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21:8247.
35. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J. L. Bodmer, M. Schroter, K. Burns, C. Mattmann, D. Rimoldi, L. E. French and J. Tschopp. 1997. Inhibition of death receptor signals by cellular FLIP. Nature 388:190.
36. Srinivasula, S. M., M. Ahmad, S. Ottilie, F. Bullrich, S. Banks, Y. Wang, T. Fernandes-Alnemri, C. M. Croce, G. Litwack, K. J. Tomaselli, R. C. Armstrong and E. S. Alnemri. 1997. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1 -induced apoptosis. J Biol Chem 272:18542.
37. Goltsev, Y. V, A. V. Kovalenko, E. Arnold, E. E. Varfolomeev, V. M. Brodianskii and D. Wallach. 1997. CASH, a novel caspase homologue with death effector domains. J Biol Chem 272:19641.
38. Shu, H. B., D. R. Halpin and D. V. Goeddel. 1997. Casper is a FADD-and caspase-related inducer of apoptosis. Immunity 6:751.
39. Hu, S., C. Vincenz, J. Ni, R. Gentz and V. M. Dixit. 1997. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 -and CD-95 -induced apoptosis. J Biol Chem 272:17255.
40. L and initiates cell death. Proc Natl Acad Sci USA 94:11333.
41. Inohara, N., T. Koseki, Y. Hu, S. Chen and G. Nunez. 1997. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc Natl Acad Sci USA 94:10717.
42. Rasper, D. M., J. P. Vaillancourt, S. Hadano, V. M. Houtzager, I. Seiden, S. L. Keen, P. Tawa, S. Xanthoudakis, J. Nasir, D. Martindale, B. F. Koop, E. P. Peterson, N. A. Thornberry, J. Huang, D. P. MacPherson, S. C. Black, F. Hornung, M. J. Lenardo, M. R. Hayden, S. Roy and D. W. Nicholson. 1998. Cell death attenuation by "Usurpin", a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ 5:271.
43. Scaffidi, C., I. Schmitz, P. H. Krammer and M. E. Peter. 1999. The role of c-FLIP in modulation of CD95 -induced apoptosis. J Biol Chem 274:1541.
44. Golks, A., D. Brenner, C. Fritsch, P. H. Krammer and I. N. Lavrik. 2005. CFLIPR-a new regulator of death receptor-induced apoptosis. J Biol Chem.
45. Krueger, A., I. Schmitz, S. Baumann, P. H. Krammer and S. Kirchhoff. 2001. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276:20633.
46. L is a dual function regulator for caspase-8 activation and CD95 -mediated apoptosis. EMBO J 21:3704.
47. Peter, M. E. and P. H. Krammer. 2003. The CD95 (APO-1/Fas) DISC and beyond. Cell Death Differ 10:26.
48. Scaffidi, C., S. Fulda, A. Srinivasan, C. Friesen, F. Li, K. J. Tomaselli, K. M. Debatin, P. H. Krammer and M. E. Peter. 1998. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17:1675.
49. Li, H., H. Zhu, C. J. Xu and J. Yuan. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491.
50. Luo, X., I. Budihardjo, H. Zou, C. Slaughter and X. Wang. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481.
51. Korsmeyer, S. J., M. C. Wei, M. Saito, S. Weiler, K. J. Oh and P. H. Schlesinger. 2000. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 7:1166.
52. Li, P., D. Nijhawan, I. Budihardjo, S. M. Srinivasula, M. Ahmad, E. S. Alnemri and X. Wang. 1997. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479.
53. Yin, X. M., K. Wang, A. Gross, Y. Zhao, S. Zinkel, B. Klocke, K. A. Roth and S. J. Korsmeyer. 1999. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400:886.
54. Wei, M. C., W. X. Zong, E. H. Cheng, T. Lindsten, V. Panoutsakopoulou, A. J. Ross, K. A. Roth, G. R. MacGregor, C. B. Thompson and S. J. Korsmeyer. 2001. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292:727.
55. Strasser, A., A. W. Harris, D. C. Huang, P. H. Krammer and S. Cory. 1995. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 14:6136.
56. Lacronique, V, A. Mignon, M. Fabre, B. Viollet, N. Rouquet, T. Molina, A. Porteu, A. Henrion, D. Bouscary, P. Varlet, V. Joulin and A. Kahn. 1996. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat Med 2:80.
57. Rodriguez, I., K. Matsuura, K. Khatib, J. C. Reed, S. Nagata and P. Vassalli. 1996. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med 183:1031.
58. Oshimi, K. 1996. Lymphoproliferative disorders of natural killer cells. Int J Hematol 63:279.
59. Green, D. R. and T. A. Ferguson. 2001. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2:917.
60. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189.
61. Martinez-Lorenzo, M. J., A. Anel, S. Gamen, Monle, P. Lasierra, L. Larrad, A. Pineiro, M. A. Alava and J. Naval. 1999. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol 163:1274.
62. Mariani, S. M., B. Matiba, C. Baumler and P. H. Krammer. 1995. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 25:2303.
63. Krammer, P. H. 2000. CD95's deadly mission in the immune system. Nature 407:789.
64. Li-Weber, M. and P. H. Krammer. 2003. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 15:145.
65. Sun, Z., C. W. Arendt, W. Ellmeier, E. M. Schaeffer, M. J. Sunshine, L. Gandhi, J. Annes, D. Petrzilka, A. Kupfer, P. L. Schwartzberg and D. R. Littman. 2000. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 404:402.
66. Cui, H., K. Matsui, S. Omura, S. L. Schauer, R. A. Matulka, G. E. Sonenshein and S. T. Ju. 1997. Proteasome regulation of activation-induced T cell death. Proc Natl Acad Sci USA 94:7515.
67. Ivanov, V N., R. K. Lee, E. R. Podack and T. R. Malek. 1997. Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: a potential role for transcription factor NF-kappa B. Oncogene 14:2455.
68. Matsui, K., S. Omura, H. Cui, S. L. Schauer, G. E. Sonenshein and S. T. Ju. 1997. Proteasome regulation of Fas ligand cytotoxicity. Eur J Immunol 27:2269.
69. Torgler, R., S. Jakob, E. Ontsouka, U. Nachbur, C. Mueller, D. R. Green and T. Brunner. 2004. Regulation of activation-induced Fas (CD95/Apo-1) ligand expression in T cells by the cyclin B1/Cdk1 complex. J Biol Chem 279:37334.
70. Sandstrom, P. A. and T. M. Buttke. 1993. Autocrine production of extracellular catalase prevents apoptosis of the human CEM T-cell line in serum-free medium. Proc Natl Acad Sci USA 90:4708.
71. Sandstrom, P. A., M. D. Mannie and T. M. Buttke. 1994. Inhibition of activation-induced death in T cell hybridomas by thiol antioxidants: oxidative stress as a mediator of apoptosis. J Leukoc Biol 55:221.
72. Devadas, S., L. Zaritskaya, S. G. Rhee, L. Oberley and M. S. Williams. 2002. Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression. J Exp Med 195:59.
73. Gulow, K., M. Kaminski, K. Darvas, D. Suss, M. Li-Weber and P. H. Krammer. 2005. HIV-1 Tat substitutes for oxidative signaling in activation induced T cell death. J Immunol 174:5249.
74. Li-Weber, M., O. Laur, K. Dern and P. H. Krammer. 2000. T cell activation-induced and HIV tat-enhanced CD95 (APO-1/Fas) ligand transcription involves NF-kappaB. Eur J Immunol 30:661.
75. Evan, G. I. and K. H. Vousden. 2001. Proliferation, cell cycle and apoptosis in cancer. Nature 411:342.
76. Igney, F. H. and P. H. Krammer. 2002. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2:277.
77. Bertin, J., R. C. Armstrong, S. Ottilie, D. A. Martin, Y. Wang, S. Banks, G. H. Wang, T. G. Senkevich, E. S. Alnemri, B. Moss, M. J. Lenardo, K. J. Tomaselli and J. I. Cohen. 1997. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas-and TNFR1 -induced apoptosis. Proc Natl Acad Sci USA 94:1172.
78. Sturzl, M., C. Hohenadl, C. Zietz, E. Castanos-Velez, A. Wunderlich, G. Ascherl, P. Biberfeld, P. Monini, P. J. Browning and B. Ensoli. 1999. Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. J Natl Cancer Inst 91:1725.
79. Cheng, J., T. Zhou, C. Liu, J. P. Shapiro, M. J. Brauer, M. C. Kiefer, P. J. Barr and J. D. Mountz. 1994. Protection from Fasmediated apoptosis by a soluble form of the Fas molecule. Science 263:1759.
80. Ugurel, S., G. Rappl, W. Tilgen and U. Reinhold. 2001. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7:1282.
81. Pitti, R. M., S. A. Marsters, D. A. Lawrence, M. Roy, F. C. Kischkel, P. Dowd, A. Huang, C. J. Donahue, S. W. Sherwood, D. T. Baldwin, P. J. Godowski, W. I. Wood, A. L. Gurney, K. J. Hillan, R. L. Cohen, A. D. Goddard, D. Botstein and A. Ashkenazi. 1998. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699.
82. Yu, K. Y., B. Kwon, J. Ni, Y. Zhai, R. Ebner and B. S. Kwon. 1999. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 274:13733.
83. Roth, W., S. Isenmann, M. Nakamura, M. Platten, W. Wick, P. Kleihues, M. Bahr, H. Ohgaki, A. Ashkenazi and M. Weller. 2001. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61:2759.
84. Reed, J. C. 2001. The survivin saga goes in vivo. J Clin Invest 108:965.
85. Ambrosini, G., C. Adida and D. C. Altieri. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917.
86. Adida, C., D. Berrebi, M. Peuchmaur, M. Reyes-Mugica and D. C. Altieri. 1998. Anti-apoptosis gene, survivin and prognosis of neuroblastoma. Lancet 351:882.
87. Dierlamm, J., M. Baens, I. Wlodarska, M. Stefanova-Ouzounova, J. M. Hernandez, D. K. Hossfeld, C. De Wolf-Peeters, A. Hagemeijer, H. Van den Berghe and P. Marynen. 1999. The apoptosis inhibitor gene AP12 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6ssociated with mucosa-associated lymphoid tissue lymphomas. Blood 93:3601.
88. L and caspase-3 -like proteases. Proc Natl Acad Sci USA 95:5724.
89. Rampino, N., H. Yamamoto, Y. Ionov, Y. Li, H. Sawai, J. C. Reed and M. Perucho. 1997. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275:967.
90. Meijerink, J. P., E. J. Mensink, K. Wang, T. W. Sedlak, A. W. Sloetjes, T. de Witte, G. Waksman and S. J. Korsmeyer. 1998. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 91:2991.
91. Soengas, M. S., P. Capodieci, D. Polsky, J. Mora, M. Esteller, X. Opitz-Araya, R. McCombie, J. G. Herman, W. L. Gerald, Y. A. Lazebnik, C. Cordon-Cardo and S. W. Lowe. 2001. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:207.
92. Fulda, S. and K. M. Debatin. 2004. Exploiting death receptor signaling pathways for tumor therapy. Biochim Biophys Acta 1705:27.
93. Lee, H. O. and T. A. Ferguson. 2003. Biology of FasL. Cytokine Growth Factor Rev 14:325.
94. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 2:1361.
95. Leithauser, F., J. Dhein, G. Mechtersheimer, K. Koretz, S. Bruderlein, C. Henne, A. Schmidt, K. M. Debatin, P. H. Krammer and P. Moller. 1993. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415.
96. Moller, P., K. Koretz, F. Leithauser, S. Bruderlein, C. Henne, A. Quentmeier and P. H. Krammer. 1994. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 57:371.
97. Muller, M., S. Wilder, D. Bannasch, D. Israeli, K. Lehlbach, M. Li-Weber, S. L. Friedman, P. R. Galle, W. Stremmel, M. Oren and P. H. Krammer. 1998. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188:2033.
98. Volkmann, M., J. H. Schiff, Y. Hajjar, G. Otto, F. Stilgenbauer, W. Fiehn, P. R. Galle and W. J. Hofmann. 2001. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J Mol Med 79:594.
99. Maeda, T., Y. Yamada, R. Moriuchi, K. Sugahara, K. Tsuruda, T. Joh, S. Atogami, K. Tsukasaki, M. Tomonaga and S. Kamihira. 1999. Fas gene mutation in the progression of adult T cell leukemia. J Exp Med 189:1063.
100. Landowski, T. H., N. Qu, I. Buyuksal, J. S. Painter and W. S. Dalton. 1997. Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266.
101. Gronbaek, K., P. T. Straten, E. Ralfkiaer, V. Ahrenkiel, M. K. Andersen, N. E. Hansen, J. Zeuthen, K. Hou-Jensen and P. Guldberg. 1998. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 92:3018.
102. Davidson, W. F., T. Giese and T. N. Fredrickson. 1998. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 187:1825.
103. Zornig, M., A. Grzeschiczek, M. B. Kowalski, K. U. Hartmann and T. Moroy. 1995. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. On cogene 10:2397.
104. Peng, S. L., M. E. Robert, A. C. Hayday and J. Craft. 1996. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med 184:1149.
105. Traver, D., K. Akashi, I. L. Weissman and E. Lagasse. 1998. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 9:47.
106. Igney, F. H. and P. H. Krammer. 2002. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 71:907.
107. Shiraki, K., N. Tsuji, T. Shioda, K. J. Isselbacher and H. Takahashi. 1997. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94:6420.
108. Niehans, G. A., T. Brunner, S. P. Frizelle, J. C. Liston, C. T. Salerno, D. J. Knapp, D. R. Green and R. A. Kratzke. 1997. Human lung carcinomas express Fas ligand. Cancer Res 57:1007.
109. Song, E., J. Chen, N. Ouyang, F. Su, M. ang and U. Heemann. 2001. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 85:1047.
110. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini and J. Tschopp. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
111. Khar, A., C. Varalakshmi, B. V. Pardhasaradhi, A. Mubarak Ali and A. L. Kumari. 1998. Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing fas-ligand: a mechanism of immune evasion. Cell Immunol 189:85.
112. Arai, H., S. Y. Chan, D. K. Bishop and G. J. Nabel. 1997. Inhibition of the alloantibody response by CD95 ligand. Nat Med 3:843.
113. Seino, K., N. Kayagaki, K. Okumura and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nat Med 3:165.
114. Behrens, C. K., F. H. Igney, B. Arnold, P. Moller and P. H. Krammer. 2001. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice. J Immunol 166:3240.
115. Igney, F. H. and P. H. Krammer. 2002. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 71:907.
116. Biancone, L., A. D. Martino, V Orlandi, P. G. Conaldi, A. Toniolo and G. Camussi. 1997. Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med 186:147.
117. Alderson, M. R., R. J. Armitage, E. Maraskovsky, T. W. Tough, E. Roux, K. Schooley, F. Ramsdell and D. H. Lynch. 1993. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 178:2231.
118. Ponton, A., M. V Clement and I. Stamenkovic. 1996. The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function. J Biol Chem 271:8991.
119. Desbarats, J., R. B. Birge, M. Mimouni-Rongy, D. E. Weinstein, J. S. Palerme and M. K. Newell. 2003. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 5:118.
120. Miwa, K., M. Asano, R. Horai, Y. Iwakura, S. Nagata and T. Suda. 1998. Caspase 1 -independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 4:1287.
121. Volpert, O. V., T. Zaichuk, W. Zhou, F. Reiher, T. A. Ferguson, P. M. Stuart, M. Amin and N. P. Bouck. 2002. Inducerstimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 8:349.
122. Wigginton, J. M., E. Gruys, L. Geiselhart, J. Subleski, K. L. Komschlies, J. W. Park, T. A. Wiltrout, K. Nagashima, T. C. Back and R. H. Wiltrout. 2001. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 108:51.
123. Debatin, K. M. and P. H. Krammer. 2004. Death receptors in chemotherapy and cancer. Oncogene 23:2950.
124. Houghton, J. A., F. G. Harwood and D. M. Tillman. 1997. Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc Natl Acad Sci USA 94:8144.
125. Kasibhatla, S., T Brunner, L. Genestier, F. Echeverri, A. Mahboubi and D. R. Green. 1998. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1:543.
126. Eichhorst, S. T., M. Muller, M. Li-Weber, H. Schulze-Bergkamen, P. Angel and P. H. Krammer. 2000. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol 20:7826.
127. Friesen, C., I. Herr, P. H. Krammer and K. M. Debatin. 1996. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2:574.
128. Micheau, O., E. Solary, A. Hammann and M. T. Dimanche-Boitrel. 1999. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 274:7987.
129. Micheau, O., A. Hammann, E. Solary and M. T. Dimanche-Boitrel. 1999. STAT-1 -independent upregulation of FADD and procaspase-3 and-8 in cancer cells treated with cytotoxic drugs. Biochem Biophys Res Commun 256:603.
130. Friesen, C., S. Fulda and K. M. Debatin. 1997. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 11:1833.
131. Fulda, S., H. Sieverts, C. Friesen, I. Herr and K. M. Debatin. 1997. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57:3823.
132. Eischen, C. M., T J. Kottke, L. M. Martins, G. S. Basi, J. S. Tung, W. C. Earnshaw, P. J. Leibson and S. H. Kaufmann. 1997. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90:935.
133. Villunger, A., A. Egle, M. Kos, B. L. Hartmann, S. Geley, R. Kofler and R. Greil. 1997. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 57:3331.
134. Kataoka, T., M. Schroter, M. Hahne, P. Schneider, M. Irmler, M. Thome, C. J. Froelich and J. Tschopp. 1998. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs and gamma irradiation. J Immunol 161:3936.
135. Langelier, Y., S. Bergeron, S. Chabaud, J. Lippens, C. Guilbault, A. M. Sasseville, S. Denis, D. D. Mosser and B. Massie. 2002. The R1 subunit of herpes simplex virus ribonucleotide reductase protects cells against apoptosis at, or upstream of, caspase-8 activation. J Gen Virol 83:2779.
136. Glaser, T., B. Wagenknecht, P. Groscurth, P. H. Krammer and M. Weller. 1999. Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells. Oncogene 18:5044.
137. Wesselborg, S., I. H. Engels, E. Rossmann, M. Los and K. Schulze-Osthoff 1999. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 93:3053.
138. Yeh, W C., J. L. Pompa, M. E. McCurrach, H. B. Shu, A. J. Elia, A. Shahinian, M. Ng, A. Wakeham, W. Khoo, K. Mitchell, W. S. El-Deiry, S. W. Lowe, D. V. Goeddel and T. W. Mak. 1998. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279:1954.
139. Hyer, M. L., C. Voelkel-Johnson, S. Rubinchik, J. Dong and J. S. Norris. 2000. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2:348.
140. Kaufmann, S. H. and D. L. Vaux. 2003. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22:7414.
141. Robertson, J. D. and S. Orrenius. 2002. Role of mitochondria in toxic cell death. Toxicology 181/182:491.
142. Owen-Schaub, L., H. Chan, J. C. Cusack, J. Roth and L. L. Hill. 2000. Fas and Fas ligand interactions in malignant disease. Int J Oncol 17:5.
143. Maecker, H. L., Z. Yun, H. T. Maecker and A. J. Giaccia. 2002. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2:139.
144. Fulda, S., E. Meyer and K. M. Debatin. 2000. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1 -converting enzyme inhibitory protein expression. Cancer Res 60:3947.
145. Kinoshita, H., H. Yoshikawa, K. Shiiki, Y. Hamada, Y. Nakajima and K. Tasaka. 2000. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95 -mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer 88:986.
146. Teitz, T., T. Wei, M. B. Valentine, E. F. Vanin, J. Grenet, V. A. Valentine, F. G. Behm, A. T. Look, J. M. Lahti and V. J. Kidd. 2000. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6:529.
147. Kamihira, S., Y. Yamada, M. Tomonaga, K. Sugahara and K. Tsuruda. 1999. Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis. Br J Haematol 107:851.
148. Min, Y. H., S. Lee, J. W. Lee, S. Y. Chong, J. S. Hahn and Y. W. Ko. 1996. Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy. Br J Haematol 93:928.
149. Medema, J. P., J. de Jong, T. van Hall, C. J. Melief and R. Offringa. 1999. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 190:1033.
150. Djerbi, M., V Screpanti, A. I. Catrina, B. Bogen, P. Biberfeld and A. Grandien. 1999. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 190:1025.
151. Pingoud-Meier, C., D. Lang, A. J. Janss, L. B. Rorke, P. C. Phillips, T. Shalaby and M. A. Grotzer. 2003. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 9:6401.
152. Trauth, B. C., C. Klas, A. M. Peters, S. Matzku, P. Moller, W. Falk, K. M. Debatin and P. H. Krammer. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301.
153. Ogasawara, J., R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda and S. Nagata. 1993. Lethal effect of the anti-Fas antibody in mice. Nature 364:806.
154. Rensing-Ehl, A., K. Frei, R. Flury, B. Matiba, S. M. Mariani, M. Weller, P. Aebischer, P. H. Krammer and A. Fontana. 1995. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 25:2253.
155. Yang, X., M. S. Merchant, M. E. Romero, M. Tsokos, L. H. Wexler, U. Kontny, C. L. Mackall and C. J. Thiele. 2003. Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res 63:1122.
156. Banelli, B., I. Casciano, M. Croce, A. Di Vinci, I. Gelvi, G. Pagnan, C. Brignole, G. Allemanni, S. Ferrini, M. Ponzoni and M. Romani. 2002. Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region. Nat Med 8:1333.
157. Fulda, S. and K. M. Debatin. 2002. IFN-gamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21:2295.
158. Lee, S. H., M. S. Shin, W. S. Park, S. Y. Kim, S. M. Dong, J. H. Pi, H. K. Lee, H. S. Kim, J. J. Jang, C. S. Kim, S. H. Kim, J. Y. Lee and N. J. Yoo. 1999. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 59:3068.
159. Shin, M. S., W. S. Park, S. Y. Kim, H. S. Kim, S. J. Kang, K. Y. Song, J. Y. Park, S. M. Dong, J. H. Pi, R. R. Oh, J. Y. Lee, N. J. Yoo and S. H. Lee. 1999. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 154:1785.
160. Lee, S. H., M. S. Shin, W. S. Park, S. Y. Kim, H. S. Kim, J. Y. Han, G. S. Park, S. M. Dong, J. H. Pi, C. S. Kim, S. H. Kim, J. Y. Lee and N. J. Yoo. 1999. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 18:3754.
161. Lee, S. H., M. S. Shin, H. S. Kim, W S. Park, S. Y. Kim, J. J. Jang, K. J. Rhim, J. Jang, H. K. Lee, J. Y. Park, R. R. Oh, S. Y. Han, J. H. Lee, J. Y. Lee and N. J. Yoo. 2000. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar. J Invest Dermatol 114:122.
162. Park, W. S., R. R. Oh, Y. S. Kim, J. Y. Park, S. H. Lee, M. S. Shin, S. Y. Kim, P. J. Kim, H. K. Lee, N. Y. Yoo and J. Y. Lee. 2001. Somatic mutations in the death domain of the Fas (Apo-1/CD95) gene in gastric cancer. J Pathol 193:162.
163. Takayama, H., T. Takakuwa, Z. Dong, N. Nonomura, A. Okuyama, S. Nagata and K. Aozasa. 2001. Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens. Lab Invest 81:283.
164. Tamiya, S., K. Etoh, H. Suzushima, K. Takatsuki and M. Matsuoka. 1998. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood 91:3935.
165. Seeberger, H., P. Starostik, S. Schwarz, C. Knorr, J. Kalla, G. Ott, H. K. Muller-Hermelink and A. Greiner. 2001. Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development. Lab Invest 81:977.
166. Pasqualucci, L., P. Neumeister, T. Goossens, G. Nanjangud, R. S. Chaganti, R. Kuppers and R. Dalla-Favera. 2001. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412:341.
167. Muschen, M., D. Re, A. Brauninger, J. Wolf, M. L. Hansmann, V. Diehl, R. Kuppers and K. Rajewsky. 2000. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res 60:5640.
168. Takakuwa, T., Z. Dong, H. Takayama, F. Matsuzuka, S. Nagata and K. Aozasa. 2001. Frequent mutations of Fas gene in thyroid lymphoma. Cancer Res 61:1382.